PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients

Aude Desnoyer,1,2 Anne-Laure Blanc,1,3 Valérie Pourcher,4,5 Marie Besson,6 Caroline Fonzo-Christe,7 Jules Desmeules,6,7 Arnaud Perrier,8 Pascal Bonnabry,1,7 Caroline Samer,6 Bertrand Guignard1,6

ABSTRACT

Objectives Potentially inappropriate medication (PIM) occurs frequently and is a well-known risk factor for adverse drug events, but its incidence is underestimated in internal medicine. The objective of this study was to develop an electronic prescription-screening checklist to assist residents and young healthcare professionals in PIM detection.

Design Five-step study involving selection of medical domains, literature review and 17 semistructured interviews, a two-round Delphi survey, a forward/back-translation process and an electronic tool development.

Setting 22 University and general hospitals from Canada, Belgium, France and Switzerland.

Participants 40 physicians and 25 clinical pharmacists were involved in the study. Agreement with the checklist statements and their usefulness for healthcare professional training were evaluated using two 6-point Likert scales (ranging from 0 to 5).

Primary and secondary outcome measures Agreement and usefulness ratings were defined as: >65% of the experts giving the statement a rating of 4 or 5, during the first Delphi-round and >75% during the second.

Results 166 statements were generated during the first two steps. Mean agreement and usefulness ratings were 4.32/5 (95% CI 4.28 to 4.36) and 4.11/5 (4.07 to 4.15), respectively, during the first Delphi-round and 4.53/5 (95% CI 4.47 to 4.56) and 4.33/5 (4.30 to 4.39) during the second (p<0.001). The final checklist includes 160 statements in 17 medical domains and 56 pathologies. An algorithm of approximately 31 000 lines was developed including comorbidities and medications variables to create the electronic tool.

Conclusion PIM-Check is the first electronic prescription-screening checklist designed to detect PIM in internal medicine. It is intended to help young healthcare professionals in their clinical practice to detect PIM, to reduce medication errors and to improve patient safety.

BACKGROUND

Improving medication safety and optimising drug prescribing are fundamental to patient safety and are priority goals of healthcare systems worldwide.1,2 Drug-related problems (DRPs) defined as an event or circumstance involving a patient’s drug treatment that actually or potentially interferes with the achievement of an optimal outcome are common in internal medicine: approximately 80% of the inpatients have at least 1 DRP, with a mean of 2–3 DRPs per patient.3–7 DRPs include subtherapeutic dosage, failure to receive drugs, adverse reactions and potentially inappropriate medication (PIM), defined as the prescribing of medications without a valid indication or with a contra-indication (overprescription); failure to prescribe a clinically indicated drug (underprescription); the occurrence of unwanted drug–drug or drug–disease interactions or the incorrect prescribing of an indicated drug (misprescription), such as duplicate prescribing, inappropriate follow-up and incorrect medication dose or duration.8 PIM is a well-known risk factor for adverse drug events and is therefore a source of morbidities.
and sometimes mortality, imposing clinical and economic burdens on patients and healthcare systems.9

Many prescription-screening checklists, such as the Beers Criteria (North America),10–14 the Assessing Care of Vulnerable Elders indicators (United States),15 16 a set of criteria developed in Australia17 and the STOPP/START criteria (Europe),18 19 have been developed to detect PIM in geriatric patients.8 20–22 Application of STOPP/START combined with education of physicians and pharmacists has been shown to be effective in minimising PIM in this population.23 However, no such checklist has been developed for general internal medicine patients. Nevertheless, multimorbidity and polypharmacy are frequent in this population4–7 and are independent risk factors for the occurrence of DRPs, whereas age is not.4 24 Geriatric checklists can be used for patients admitted in internal medicine, but such checklists are often much more focused on geriatric pathologies, not necessarily relevant in internal medicine (eg, dementia and Alzheimer’s disease). Some pathologies and interventions commonly encountered in internal medicine are almost never covered by geriatric checklists (eg, obesity, contraception, infectious diseases, transplantation, renal failure and neuropathic pain).

Therefore, we have developed a new international electronic prescription-screening checklist for use with adults in general internal medicine. Specifically, we adapted the approach used by Gallagher et al18 with the aim of achieving an international, multidisciplinary consensus on a checklist of statements that includes all types of PIMs, covers pathologies commonly observed in internal medicine and is available as an electronic version to assist and train junior healthcare professionals, in PIM detection in their daily practice and to improve medication safety.

METHODS
This study was split into five steps (figure 1).

First step: Selection of medical domains
A multidisciplinary international research group consisting of four internists, five clinical pharmacists, and three clinical pharmacologists from France and Switzerland was constituted to supervise the project. The group was responsible for selecting the medical domains (eg, medical specialties and medical acts, such as vaccinations and transplants) and subdomains (including pathologies, therapeutic classes and medical procedures (eg, prevention/prophylaxis, analgesia)) to be addressed in the draft version of the checklist. Selections of medical domains and subdomains were based on the main diseases observed in patients admitted to internal medicine,25 the therapeutic classes associated with adverse drug events in these patients,7 the Institute for Safe Medication Practices’ list of high-alert medications that includes drugs that bear an increased risk of causing significant patient harm when they are used in error26 and some of the pathologies included in previously published geriatric prescription-screening checklists.20 22 25 27 AD led the project and is the principal investigator in this study.

Second step: Literature reviews, semistructured interviews and draft criteria agreement
During this step, statements of potential interest for a prescription-screening checklist dedicated to adults
in internal medicine (excluding pregnant women and inpatients with low life expectancy or requiring palliative care) were identified and selected for inclusion in the draft checklist.

**Literature reviews and semistructured interviews**

For each medical domain and subdomains selected during the first step, an extensive literature review of evidence-based optimal and inappropriate medication prescriptions was conducted. It preceded a semistructured interview, with a specialist physician of the domain to be addressed during the interview, working in the Geneva University Hospitals. The literature review process is detailed in the online supplementary appendix 1. Each interview comprised four parts: (1) project presentation, (2) presentation of statements previously published in geriatric prescription-screening checklists and statements related to the medical field addressed during the interview, (3) submission to the specialist of the pathologies and statements formulated during the literature review and (4) suggestions by the specialist of pathologies and statements to be added to the draft version. The semistructured interview topics and guide are provided in the online supplementary appendix 1 and supplementary table 1.

**Draft criteria agreement**

After semistructured interviews, redundant statements related to two or more domains and validated by at least two medical specialists were merged and the formulation of each remaining statement was standardised by the principal investigator. Finally, the statements were submitted to five members of the research group—three internists, one clinical pharmacist and one clinical pharmacologist—who anonymously rated the usefulness of the statements for practice in internal medicine by using a 5-point Likert scale ranging from 1 (not useful at all) to 5 (very useful). Statements with a mean rating greater than or equal to 3 were retained for the next step.

**Third step: Delphi study**

A two-round Delphi method was used to generate a consensual validation of the statements that were included in the draft checklist (figure 2).

**Experts’ recruitment**

To represent the views of the professional groups engaged in medication management in internal medicine, a panel of experts in French-speaking countries was recruited in roughly equal numbers by profession (internists and clinical pharmacists with a practice in internal medicine), hospital teaching status (university
and non-teaching hospitals) and country (Canada (Québec), Belgium, France and Switzerland). The recruitment process is described in the online supplementary appendix 1.

**Delphi rounds**

We used the SurveyMonkey website to conduct the Delphi survey. As detailed in the online supplementary appendix 1, 1 week before each round, experts received by email the relevant documents to validate statements. For each round, the experts had to indicate their level of agreement with each statement using a 6-point Likert scale: 0, no opinion; 1, strongly disagree; 2, disagree; 3, neither agree nor disagree; 4, agree and 5, strongly agree. Using a second 6-point Likert scale, ranging from 1 (not useful at all) to 5 (very useful) (0, no opinion), the experts also had to rate the usefulness of each statement for daily practice and for training of students, residents and young healthcare professionals in internal medicine or clinical pharmacy. Finally, the experts were invited to add propositions including comments, modifications, references and useful links to each statement.

In accordance with previous studies, we used the following two validation rules. Statements that received the agreement (rating 4 or 5) of more than 65% of the experts after the first round were retained, were eventually modified according to the experts’ comments and were subjected to the second round.28 29 Statements with a lower percentage of experts’ agreement were excluded (ie, ≤65% of the experts rating 4 or 5 the statement). After the second round, only statements that received the agreement of more than 75% of the experts were retained for the final version of the checklist. The usefulness rating was considered a secondary endpoint and was not used to exclude statements. The expected durations of the first and second rounds were 3 and 2 weeks, respectively. For each round, reminders were sent to the experts, as described in the online supplementary appendix 1.

**Integration of experts’ propositions**

To reduce potential bias due to a single person doing all the data management, we used investigator triangulation to integrate comments and propositions from the experts.30 This triangulation process is detailed in the online supplementary appendix 1.

**Fourth step: Forward/back-translation process**

A forward/back-translation process was applied to translate the checklist in English.31 Briefly, the checklist was forward-translated into English by a bilingual native-English-speaking physician from Elsevier Translation Service who was familiar with French-speaking culture and with the terminology of internal medicine. Then, a bilingual native-French-speaking internist back-translated the checklist into French. Finally, three members of the research group identified and resolved any instances of inadequate expression between the back translation and the original version.

**Fifth step: Electronic tool development**

To facilitate the use of the tool in daily practice, an electronic version was created. A web-designer and a webmaster were involved in the development of a website and a web-mobile application. A ‘Screening’ function, allowing to select for a specific patient, his/her comorbidities and/or medications and to present only relevant statements, a ‘Favourite’ function to give quick access to statements identified as favourite and a ‘Learning’ function to allow users to follow their progress in the acquisition of recommendation knowledge were included in the application. To develop the ‘Screening’ function, members of the research group identified medications, and corresponding anatomical therapeutic chemical code, from Belgium, France, Quebec and Switzerland, using national databases.32–35 A dictionary of synonyms of subdomains included in the tool was also created. Then, an algorithm combining each validated statement with corresponding subdomains and medications was developed.

**Statistical methods**

Analyses were performed with Prism 6 software (GraphPad Software, San Diego, California, USA). Variables were summarised as numbers (percentages) for categorical variables, the mean and 95% CI for continuous variables. During each Delphi round and for each statement, the mean agreement rating, the mean usefulness rating, the percentage of experts who rated each statement as 4 or 5, the participation rate and the mean number of experts who responded with ‘no opinion’ (0) were evaluated. For each statement, the mean agreement and usefulness ratings were compared between the first and the second rounds using Mann–Whitney tests. p Values are two-tailed, with a significance level of 0.05.

**Ethics considerations**

The Swiss Law on Medical Research Involving Human Subjects did not require us to seek ethical approval as no participation by patients or use of patients’ data, human tissue or animals were involved in this study.

**RESULTS**

**First and second steps**

The principal investigator conducted 17 semistructured interviews, one each with 17 specialist physicians. Seventeen medical domains and 69 subdomains associated with pathologies, therapeutic classes, medical procedures and DRPs commonly observed in internal medicine were identified. After the semistructured interviews and suppression or merging of redundant statements, 187 statements remained. Among them, 21 mean ratings were less than 3 (2.44 (2.33 to 2.55)) and were considered to be not useful for practice in internal medicine. These statements were excluded from the draft checklist (eg, statements related to sleep apnoea, cystic fibrosis, polymyalgia rheumatica and myasthenia gravis). The remaining 166 statements involved 17 medical domains and 65
subdomains that received a mean usefulness rating of 3.99/5 (3.89 to 4.08).

**Third step: Delphi survey**

Forty experts from 22 hospitals met the inclusion criteria and agreed to join the Delphi survey (Table 1). During the first round, participation rate was 97.5% (39/40). A median of 37 (IQR 25%–75%: 36–38) experts rated their agreement for each statement, with a median of 2 experts with ‘no opinion’ per statement. Only one statement was evaluated by fewer than 30 experts (n=28); because this statement completed the first-round validation rule, it was clarified and modified according to the experts’ comments and submitted for the second round of Delphi. The mean agreement and usefulness rating were 4.32/5 (95% CI 4.28 to 4.36) and 4.11/5 (4.07 to 4.15), respectively according to the 0–5 Likert scales. Six statements were removed according to the validation rule for the first round (Table 2). Of the 166 statements evaluated in the first Delphi round, 152 (91.5%) were rated by more than 65% of the experts as useful or very useful for the training of students, residents and young healthcare professionals in internal medicine and clinical pharmacy. The experts made 677 comments, which led the investigator triangulation group to add 3 new statements, modify 84, and merge 3 pairs of statements. The remaining 160 statements were retained and subjected to the second round.

All the experts who completed the first round completed the second round (participation rate 100% (39/39)). They rated their level of agreement for 100% of the statements, without selecting the ‘no opinion’ option. The mean agreement and usefulness ratings were 4.53/5 (95% CI 4.51 to 4.56) and 4.36/5 (4.33 to 4.39), respectively (see online supplementary table 1). Both ratings were higher than the corresponding ratings from the first round (p<0.001). After the second round, all 160 submitted statements were validated according to validation rule for this round. Of these statements, 156 (97.5%) were rated as useful or very useful by more than 75% of the experts (see online supplementary table 2). During the second round, the experts made 399 propositions and on the basis of these propositions, 74 statements were clarified.

The final checklist includes 160 statements, divided into 17 medical domains and 52 subdomains (Table 3). Seventy-four (46%) statements are related to underprescription,

| Table 2 | Statements rejected by the expert panel during the first round of the Delphi survey |
|---------|--------------------------------------------------------------------------------------------|
| Type of PIM | Medical domain and subdomain | Rejected statement | Proportion of experts who agreed or strongly agreed with the statement (%) |
| Underprescription | Cardiology: Dyslipidaemia and hypolipidemias | Prescribe fibrates as a first-line treatment in case of isolated hypertriglyceridaemia when pharmacological treatment is necessary* | 56.4 |
| Overprescription | Pneumology: Chronic respiratory diseases | Avoid prescribing BZD or opiates in patients with chronic respiratory disease when an alternative is available or monitor respiratory function closely | 63.2 |
| Underprescription | Nephrology: Renal failure | Prescribe or continue treatment with statins in patients with chronic renal failure* | 57.1 |
| Other | Neurology: Epilepsy and antiepileptics | When possible, keep the same antiepileptic brand name in hospitalised patients or re-evaluate treatment with a specialist | 55.3 |
| Underprescription | Psychiatry: Insomnia, sedatives and hypnotics | Prescribe BZD or a BZD-like drug as a first-line treatment in case of insomnia when pharmacological treatment is necessary | 57.9 |
| Overprescription | Psychiatry: Insomnia, sedatives and hypnotics | Avoid prescribing drugs that may exacerbate insomnia* in patients with chronic insomnia | 53.8 |

*Additional information provided to experts.
Table 3  Final list of statements included in PIM-Check

| PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine |
|---|
| This tool is designed for quick detection of underprescription: UP, overprescription: OP, drug interaction: DDI or other kind of potentially inappropriate medications (e.g., therapeutic adaptations, treatment re-evaluations, improper drug use): OTH, that may be dangerous for patients hospitalised in internal medicine (excluding pregnant women and patients with low life expectancy or requiring palliative care). It is organised by major physiological systems and pathologies. This is not a replacement for a clinical and biological evaluation by a clinician. The proposals are only applicable in the event there is no patient-specific contraindication. This tool was validated using a Delphi method including 40 international experts from Belgium, France, Québec and Switzerland. Some drugs listed may not be available in each country. |

| CARDIOLOGY |
|---|
| Heart failure |
| 1 UP | Start ACEI or ARB |
| Prescribe or continue long-term ACEI treatment in patients with HF (or ARB in case of intolerance) |
| 2 UP | Start beta-blocker treatment |
| Prescribe or continue long-term beta-blocker treatment* in patients with HF |
| 3 UP | Start aldosterone antagonist when LVEF≤35% despite optimal treatment |
| Consider prescribing an aldosterone antagonist in HF patients with LVEF≤35% despite treatment with ACEI, or ARB and beta-blocker at the recommended or maximum tolerated doses |
| 4 OP | Drugs that may exacerbate HF |
| Avoid prescribing drugs* that may exacerbate HF, drugs that are rich in sodium** and antiarrhythmics (except for digoxin and amiodarone) in HF patients |

| Dyslipidaemia and hypolipidemics |
|---|
| 5 UP | Dyslipidaemia and high cardiovascular risk: start statins |
| Prescribe or continue treatment with statins in patients with a high cardiovascular risk or adapt lifestyle and dietary measures and the treatment intensity based on that risk (moderate, high or very high) |
| 6 UP | Dyslipidaemia, hypercholesterolaemia: start statins as a first-line treatment |
| Prescribe statins as a first-line treatment in case of mixed dyslipidaemia or hypercholesterolaemia when pharmacological treatment is necessary* |
| 7 DDI | Statins and DDI |
| Evaluate the risk of DDIs and adapt the treatment if statins are introduced or if treatment is modified in patients receiving statins |
| 8 OP | Avoid combining statins and fibrates |
| Avoid combining statins and fibrates and prohibit the statin/gemfibrozil combination |

| Stable ischaemic heart disease |
|---|
| 9 UP | Start beta-blocker treatment |
| Prescribe or continue beta-blocker treatment in patients with ischaemic heart disease |
| 10 UP | Start low-dose aspirin |
| Prescribe or continue treatment with low-dose aspirin in patients suffering from ischaemic heart disease (when there is no contraindication*) |
| 11 UP | Start statins |
| Prescribe or continue statins in patients suffering from stable ischaemic heart disease |

| Secondary prevention of acute STEMI or NSTEMI |
|---|
| 12 Other | Start lifestyle and diet modifications |
| Encourage patients having undergone a STEMI or NSTEMI to participate in a secondary prevention programme, specifically aiming to adapt their diet, control their weight, engage in physical activity, stop smoking and improve compliance with treatment |
| 13 UP | Start beta-blocker treatment |
| Prescribe or continue long-term beta-blocker treatment after a STEMI or NSTEMI |
| 14 UP | Dual antiplatelet therapy? |
| Prescribe or continue treatment by dual antiplatelet therapy for up to 12 months after a STEMI or NSTEMI, followed by long-term antiplatelet monotherapy (first-line treatment = low-dose aspirin) |

Continued
| No. | Action | Details |
|-----|--------|---------|
| 15  | Start statins | Prescribe or continue statins after STEMI or NSTEMI |
| 16  | Start ACEI or ARB | Prescribe or continue treatment with ACEI for at least 30 days following a STEMI or NSTEMI and then, on a long-term basis, in particular in the presence of an aggravating factor* (or an ARB in case of intolerance) |
| 17  | Start antihypertensive drug treatment | Begin antihypertensive drug treatment with a first-line drug* alone or in combination if pharmacological treatment of BP is necessary**. Combine it with lifestyle and diet modifications*** |
| 18  | Favour ACEI or ARB in patients with diabetes/CKD/HF/STEMI/NSTEMI and HBP | Favour an ACEI or ARB combined or without another first-line antihypertensive drug to treat high BP in patients with diabetes or in patients with microalbuminuria/proteinuria, CKD, HF or history of STEMI or NSTEMI |
| 19  | Resistant high BP | Seek a secondary cause of high BP and then optionally add an aldosterone antagonist*, amiloride or an alpha 1 blocker in case of true resistant HTN** |
| 20  | Drugs that can exacerbate high BP | Exercise caution in using drugs that may increase BP* or that are rich in sodium** in patients with high BP |
| 21  | Avoid loop diuretic as a first-line treatment | Do not prescribe a loop diuretic as a first-line treatment to treat high BP |
| 22  | Start statins | Prescribe statins in patients with non-cardioembolic and non-haemorrhagic TIA or stroke |
| 23  | Start antiplatelet therapy | Prescribe a preventive antiplatelet therapy* in patients with non-cardioembolic and non-haemorrhagic TIA or stroke |
| 24  | Adjust digoxin dose | Reduce or adjust digoxin dose depending on the digoxin serum levels in elderly patients or patients with renal failure; favour an alternative when possible |
| 25  | Digoxin and DDIs | Evaluate the risk of DDIs and adapt treatment in case new treatment is introduced in a patient receiving digoxin (in particular with Pgp inhibitors) |
| 26  | Start oral anticoagulation | Prescribe or continue oral anticoagulation* in patients suffering from non-valvular AF whose CHA2DS2-VASc** ≥1. In case of treatment with VKA, adapt the doses to obtain an INR between 2 and 3 |

**ANGIOLOGY/HAEMOSTASIS**

**Oral anticoagulants**

| No. | Action | Details |
|-----|--------|---------|
| 27  | Anticoagulation: start patient education | Provide patient education for patients receiving oral anticoagulation (or the caregiver) |
| 28  | Anticoagulation: prevent the inappropriate administration of anticoagulant | Verify the appropriateness of the administration for an oral anticoagulant taken by a patient (dosage, frequency and time of administration) with the indication, the usual treatment and the prescribed molecule (in particular for DOACs: the number of doses/day and the administration conditions) |
| 29  | VKAs: Vitamin K1 administration | Favour the OR in case of VKA overdose requiring the administration of Vitamin K1. |
| 30  | Switching from VKA to DOAC | Consider a DOAC switch in patients who were already treated with VKA only if the INR is not kept in the target zone despite monitoring and correct observance or in case of intolerance. Continue VKA treatment if the latter is effective and well tolerated |

*Continued*
## Table 3  Continued

### PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine

|   | Anticoagulation and renal function | Anticoagulation and DDIs |
|---|----------------------------------|--------------------------|
| 31 | Evaluate renal function* and adjust the doses to the CrCl if a DOAC is introduced in a patient. Favour VKA treatment if the CrCl is <30 mL/min | Evaluate the risk of DDIs* and adapt the treatment if a new drug is introduced in patients receiving an oral anticoagulant |

#### Deep vein thrombosis, pulmonary embolism, venous thromboembolism

|   |   |   |
|---|---|---|
| 33 | DVT/PE: start anticoagulation | Prescribe or continue anticoagulation for at least 3 months* in case of proximal DVT and/or PE. In case of treatment with VKA, adapt the doses to obtain an INR between 2 and 3 |
| 34 | Idiopathic VTE: start anticoagulation | Prescribe or continue anticoagulation for at least 3 months or long term with annual re-evaluation in case of idiopathic VTE or with a major persistent risk factor* |
| 35 | DVT/PE/VTE: start prophylactic anticoagulation | Prescribe prophylactic anticoagulation* in patients who are hospitalised for acute medical affection for an anticipated duration of at least 3 days and with a high risk of thrombosis** and/or in patients who are hospitalised for surgical procedure with a moderate or high risk of thrombosis |

### PNEUMOLOGY

#### Chronic respiratory diseases

|   |   |   |
|---|---|---|
| 36 | New inhalation drug delivery device: start patient education | Provide individualised patient education (or caregiver) if a new inhalation drug delivery device is prescribed and ensure that it is used properly |
| 37 | Use of the holding chamber | Favour the use of a holding chamber for the administration of products in a metered-dose inhaler in the event of worsening chronic respiratory disease or poor hand-lung coordination |
| 38 | ICS mode of administration | Favour taking ICS before meals and rinse out the mouth and gargle or brush teeth after inhalation |
| 39 | Caution with non-cardioselective beta-blocker | Favour a cardioselective beta-blocker* when it is indicated in patients with asthma or COPD |

### Asthma

|   |   |   |
|---|---|---|
| 40 | Asthma and long-term treatment: start ICS as a first-line treatment | Prescribe, as a first-line treatment, low-dose ICS in patients with mild persistent asthma* requiring background treatment |
| 41 | Asthma and long-term treatment: avoid long-acting beta2-agonists as a first-line treatment or as monotherapy | Do not prescribe as first-line treatment or as monotherapy a long-acting beta2-agonists to treat asthma |
| 42 | Asthma and long-term treatment: add long-acting beta2-agonists as a second-line treatments | Add long-acting beta2-agonists (favoured) or increase the inhaled corticosteroid doses in patients with asthma for whom taking a low dose ofICS alone is not sufficient |

### Chronic obstructive pulmonary disorder

|   |   |   |
|---|---|---|
| 43 | COPD and long-term treatment: start a beta2-agonist or anticholinergics as a first-line treatment | Prescribe an inhaled bronchodilator (β2-mimetic or anticholinergics) as a first-line pharmacological treatment for COPD |
| 44 | COPD and long-term treatment: avoid ICS as a first-line treatment or as a monotherapy | Do not prescribe ICS as a first-line treatment and as a monotherapy to treat COPD |

### NEPHROLOGY

#### Renal failure

|   |   |   |
|---|---|---|
| 45 | Adjust drug doses | Adjust drug doses if a new treatment is introduced in a patient with renal failure or in case of a significant modification of renal function |
**PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine**

| OP | RF: be careful with nephrotoxic drugs and or adjust doses of drugs that are excreted by the kidneys Avoid nephrotoxic drugs* and exercise caution in prescribing drugs that are excreted by the kidneys in chronic renal failure patients or patients having a pathology that may cause acute renal failure, or adjust doses and check renal function |
| 46 | Correct iron deficiency before starting ESA treatment Correct any iron deficiency before starting ESA treatment and then prescribe a sufficient iron supplement* in combination with ESA treatment |
| 47 | Prescribe, if needed and in collaboration with a nephrologist, an ESA in chronic renal failure patients with a Hb level<10g/dL or bothersome symptoms, despite sufficient iron supplementation. The Hb target is approximately 11.5g/dL (between 10 and 12g/dL) while avoiding exceeding 12g/dL |
| 48 | Calcium, vitamin D and/or phosphate-binding agents Continue or adjust calcium, vitamin D supplementation and/or phosphate-binding agents (to be taken with food) in chronic renal failure patients |
| 49 | Start ACEI or ARB Prescribe or continue treatment with ACEI or ARB in chronic renal failure patients with albuminuria* or chronic renal failure patients with diabetes and microalbuminuria** |
| UP | Correct iron deficiency before starting ESA treatment and then prescribe a sufficient iron supplement* in combination with ESA treatment |

**Benign prostatic hyperplasia**

| OP | Drugs that may exacerbate BPH Avoid anticholinergic* or sympathomimetic drugs in patients with BPH or use with caution and under monitoring |

**GASTROENTEROLOGY**

| OP | Peptic ulcer disease prevention: PPI treatment started before hospitalisation Re-evaluate the continuation of PPI treatment that started more than 8 weeks before hospitalisation |
| 52 | PPI treatment started during hospitalisation Stop PPI treatment before patient discharge if that treatment started during hospitalisation to prevent bleeding |
| 53 | PPI re-evaluate treatment dose and duration Do not exceed a dose equivalent* to 20mg/day of oral esomeprazole if empiric PPI treatment is started during hospitalisation and do not extend past 8 weeks without gastroenterologist opinion or endoscopic evaluation |
| 54 | PPI: prescription with no valid indication Do not prescribe a PPI to prevent lesions that are caused by taking NSAIDs, CS or aspirin alone in the absence of a risk factor* |
| 55 | Be careful with drugs that may exacerbate ulcer disease Avoid prescriptions that may cause digestive bleeding* in patients suffering from peptic ulcer disease or make sure that it is combined with a PPI |
| 56 | Hepatic impairment and cirrhosis Avoid the use or adjust doses of potentially hepatotoxic drugs or of drugs that are metabolised by the liver* when started in patients with hepatic impairment |
| 57 | Hepatic encephalopathy: lactulose and lactitol Consider prescribing disaccharides that are not generally absorbable at high doses in patients suffering from hepatic encephalopathy |
| 58 | Diarrhoea without investigation: avoid antimotility agents Do not use antimotility agents* in case of mucohaemorrhagic diarrhoea, diarrhoea combined with high fever or postantibiotic diarrhoea without additional investigation |
| 59 | Testing for Clostridium difficile infection Systematically look for a C difficile infection in case of nosocomial diarrhoea (>72 hour), postantibiotic diarrhoea or diarrhoea with no other aetiology |

**Testing for Clostridium difficile infection**

Systematically look for a C difficile infection in case of nosocomial diarrhoea (>72 hour), postantibiotic diarrhoea or diarrhoea with no other aetiology

Continued
### PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine

| Table 3 | Continued |
|---------|-----------|

|   | Treatment of *Clostridium difficile* infection  |
|---|---------------------------------------------|
| 61 | Prescribe as a first-line treatment for a first episode of *Clostridium difficile* infection:  |
|   | ▶ metronidazole (OR or intravenous), in the case of a mild to moderate episode  |
|   | ▶ vancomycin (OR), in the case of a severe episode  |

#### Constipation

|   | Drugs that may exacerbate constipation  |
|---|---------------------------------------|
| 62 | Avoid or use with caution drugs that may cause iatrogenic constipation* in patients suffering from constipation, or monitor and treat any aggravation  |

#### RHEUMATOLOGY

### Gout

|   | Acute gout: NSAID and/or colchicine or glucocorticoid as a first-line treatment  |
|---|--------------------------------------------------------------------------------|
| 63 | Prescribe as a first-line treatment an NSAID and/or oral colchicine or even a glucocorticoid* to patients suffering from acute gout  |

|   | Gout and long-term treatment: start allopurinol as a first-line treatment  |
|---|-------------------------------------------------------------------------|
| 64 | Prescribe allopurinol as a first-line treatment to patients for whom pharmacological treatment seeking to reduce uric acid levels is necessary*  |

|   | Gout and long-term treatment initiation: add an NSAID or low-dose colchicine  |
|---|----------------------------------------------------------------------------|
| 65 | To avoid a gout attack, prescribe an NSAID or low-dose colchicine for the titration duration of a hypouricaemic background treatment or if the dose is changed  |

|   | Drugs that may exacerbate gout  |
|---|------------------------------|
| 66 | When an alternative is available, avoid or use with caution drugs that may cause an increase in uric acid levels and gout attacks* in patients suffering from gout  |

#### Rheumatoid arthritis

|   | MTX and monitoring  |
|---|---------------------|
| 67 | Monitor hepatic transaminases, complete blood count and renal function before starting treatment with MTX and then regularly during treatment (in particular if combined with other hepatotoxic, haematotoxic or nephrotoxic drugs*)  |

|   | MTX: start folic acid  |
|---|------------------------|
| 68 | Prescribe preventive treatment with daily or weekly folic acid in patients receiving long-term MTX  |

|   | Avoid long-term CS  |
|---|--------------------|
| 69 | Re-evaluate with a specialist and optionally stop long-term corticosteroid treatment in patients with RA with prolonged remission  |

#### Corticosteroids and osteoporosis

|   | Long-term CS: start patient education* to those receiving new long-term corticosteroid treatment (or caregivers)  |
|---|---------------------------------------------------------------|
| 70 | Long-term CS and prevention of osteoporosis: start calcium/vitamin D  |
|   | Evaluate intake and prescribe calcium and vitamin D if needed to patients receiving corticosteroid treatment for an anticipated duration of ≥3 months (irrespective of the dose)  |

|   | Long-term CS and prevention of osteoporosis: start bisphosphonates  |
|---|------------------------------------------------------------------|
| 71 | Prescribe bisphosphonates to patients receiving CS with an increased risk of fracture* or to patients with a high risk of osteoporosis receiving long-term CS**  |

|   | CS and bisphosphonates: prevent inappropriate administration  |
|---|---------------------------------------------------------------|
| 72 | Correct any hypercalcaemia or vitamin D deficiency* before beginning treatment with bisphosphonates.  |
|   | Prescribe bisphosphonates in the morning on an empty stomach** with a large glass of lowly mineralised water, separate from other medicines***, informing the patient to remain seated or standing for at least 30 min  |

#### NEUROLOGY

### Epilepsy and antiepileptics

|   | Drugs that may exacerbate epilepsy  |
|---|-----------------------------------|
| 73 | Avoid or use with caution treatments that may lower the seizure threshold* in an patient with epilepsy if an alternative is available  |

Continued
## PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine

| 75 DDI  | Antiepileptic and DDIs  |
|---------|--------------------------|
|         | Evaluate the risk of DDIs, and adjust the treatment if a new treatment is introduced in patients receiving antiepileptics (in particular with CYP and/or Pgp inducers/inhibitors)* |

| 76 UP  | Antiepileptic and DDIs with contraception  |
|---------|-------------------------------------------|
|         | Use effective contraception means* if possible other than combined oral or intra-vaginal contraceptives, patches and pure progestogen pills in women of childbearing age who are treated with an enzyme-inducing anti-epileptic** and who have not become pregnant |

### Parkinson's disease and Parkinson's medications

| 77 UP  | Prevent the inappropriate administration of Parkinson's disease treatment  |
|---------|--------------------------------------------------------------------------|
|         | Continue treatment for Parkinson's disease at the usual doses, times and dosing forms in case of hospitalisation. Adapt the dosing form and the dose in case of fasting or difficulty swallowing |

| 78 OP  | Parkinson's disease and antinausea neuroleptics: prefer domperidone  |
|---------|---------------------------------------------------------------------|
|         | Avoid using dopamine antagonist antinausea medications crossing the haematoencephalic barrier to treat nausea and vomiting in patients with Parkinson's disease. Prefer domperidone |

### Psychiatry

### Psychotropic illness and drugs

| 79 OP  | Avoid prescribing two psychoactive drugs from the same therapeutic class  |
|---------|------------------------------------------------------------------------|
|         | Avoid prescribing two psychoactive drugs from the same therapeutic class without seeking a specialised opinion |

### Depression and antidepressants

| 80 UP  | Optimise the dose of an antidepressant medication if a suboptimal response is observed  |
|---------|-----------------------------------------------------------------------------------|
|         | Do not stop an insufficiently effective antidepressant treatment before optimising the dose up to the effective dose and verifying patient observance, except in the case of side effects |

| 81 UP  | Severe depression: start SSRI as a first-line treatment  |
|---------|--------------------------------------------------------|
|         | Prescribe an antidepressant* with or without combining psychotherapy in patients suffering from severe depression |

### Insomnia, sedatives and hypnotics

| 82 OP  | Hypnotic: Treatment duration and re-evaluation  |
|---------|-----------------------------------------------|
|         | Re-evaluate hypnotic treatment every 2 weeks and on hospital discharge. Do not stop hypnotic treatment abruptly |

| 83 OP  | Hypnotics: drugs to avoid as a first-line treatment  |
|---------|----------------------------------------------------|
|         | Do not prescribe sedative neuroleptics or antihistamines as a first-line treatment for insomnia (except with specific indications) |

### Schizophrenia and neuroleptics

| 84 DDI  | Neuroleptics: Drugs that prolong the QT interval  |
|---------|--------------------------------------------------|
|         | Avoid prescribing drugs that may prolong the QT interval* in patients receiving a neuroleptic, in particular if their pre-treatment QT interval is long or when there is a risk of torsade de pointes |

### Pain and Analgesia

### Neuropathic pain

| 85 UP  | Neuropathic pain: start an anticonvulsant* or an antidepressant** as a first-line treatment  |
|---------|--------------------------------------------------------------------------------------------|
|         | Prescribe as a first-line treatment an anticonvulsant* or an antidepressant** to treat chronic neuropathic pain requiring pharmacological treatment |

| 86 UP  | Neuropathic pain: combine analgesics as a second-line treatment  |
|---------|-----------------------------------------------------------------|
|         | Potentially combine an opiate antalgic with a first-line drug* in case of chronic neuropathic pain after the failure of two monotherapies or a bi-therapy of first-line drugs |

### Acute pain and opiates

| 87 UP  | Start opioids in the case of acute moderate to severe pain  |
|---------|------------------------------------------------------------|
|         | Prescribe an opiate antalgic in the case of moderate (level 2) to severe (level 3) acute pain, preferably orally, when allowed by the patient’s clinical situation (VAS>4 according to the WHO scale) |

| 88 Other  | Analgesia and opioids: switching and equianalgesic dose ratios  |
|-----------|---------------------------------------------------------------|
|           | Switch opioids* and apply the rules of equianalgesic dose ratios to determine the initial dose to be administered in patients with side effects, in case of inefficacy despite correct titration, in case of harmful drug interactions or if a change in the administration route is necessary |

---

* DDIs = Drug-drug interactions  
** CYP = CYP450 enzymes  
* Pgp = P-glycoprotein  
* DDI = Drug-drug interaction  
* UP = Use precaution  
* OP = Omit precaution  
* VAS = Visual Analogue Score

---

Table 3 Continued
Table 3  Continued

PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine

| Number | Segment | Description |
|--------|---------|-------------|
| 89 DDI | Opioids | Combine opioids of different release rates  Avoid combining two opioids with the same release kinetics or combining pure agonists–partial agonists |
| 90 UP  | Opioids | Opioids: start prophylactic measures* to prevent constipation  Take prophylactic measures* to prevent constipation from the start of an opioid treatment |
|        | Migraines | Start a triptan for patients not responding to NSAIDs +/- in combination  Prescribe a triptan in the case of a migraine attack not responding to NSAIDs +/- in combination* or in case of severe migraine  Start migraine prophylaxis  Prescribe a background treatment for migraines in patients with more than two incapacitating migraines/week or very frequently using migraine medication* |
| 91 UP  | Urinary infections | Urinary tract infection: replace the urinary catheter before starting antibiotic treatment*  Remove the urinary catheter or change it before starting suitable antibiotic treatment* in patients with urinary infection with a catheter in place for more than 2 weeks |
| 92 UP  | Pulmonary-related and tuberculosis-related infections | Pneumonia: use beta-lactam, macrolide and/or fluoroquinolone as empirical therapy  Prescribed an antibiotic from the family of beta-lactam, macrolide and/or fluoroquinolone, depending on the gravity factors and local recommendations, in empirical therapy for community-acquired pneumonia in hospitalised patients  Tuberculosis: treatment for at least 6–18 months  Continue antituberculosis treatment for at least 6–18 months (depending on the location and the germ) in patients who are treated for active tuberculosis  Anti-tuberculosis drugs: be careful with potentially hepatotoxic drugs*  Avoid or use with caution potentially hepatotoxic drugs* in patients who are treated with antituberculosis drugs, and monitor the hepatic function closely  Rifampicin and DDIs  Evaluate the risk of DDIs and favour the use of drugs not interacting* with rifampicin or adapt treatment in patients treated with rifampicin |
| 93 Other | Abdominal infections | Intra-abdominal infection: antibiotics covering anaerobic germs*  Prescribe an antibiotic covering, in particular, anaerobic germs* as an empirical treatment of a serious acute intra-abdominal infection |
| 94 UP  | Endocarditis | Endocarditis prophylaxis: only in patients at very high risk* and undergoing a very high-risk procedure**  Prescribe preventive endocarditis treatment only in patients at very high risk* and undergoing a very high-risk procedure** for bacterial endocarditis |
| 95 UP  | Osteoarticular infections | Osteoarticular infection: antibiotics with correct bone penetration*  Prescribe a highly bioavailable antibiotic with correct bone penetration* that is suitable for the germ and its sensitivity when it is identified during an osteoarticular infection |
| 96 OP  | HIV infection | Evaluate the risk of DDIs and favour the use of drugs not interacting* with rifampicin or adapt treatment in patients treated with rifampicin |
| 97 DDI | HIV infection and cardiovascular risk: start statins | HIV infection: HAART and DDIs  Evaluate the risk of DDIs and favour the use of drugs with no interaction with HAART, or adjust the doses if a new treatment is started in patients infected with HIV who are treated with HAART  HIV infection and cardiovascular risk: start statins  Prescribe statins to patients infected with HIV, considering the DDIs. The therapeutic objective in those patients is determined based on their cardiovascular risk level* |
| 98 UP  | Hepatitis C virus infection | |

Continued
### Table 3  Continued

**PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine**

| PIM-Check | Medication Recommendation |
|-----------|---------------------------|
| 103       | HCV infection: direct-acting antivirals against HCV and DDIs  
Evaluate the risk of DDIs*, and adapt the treatment if a new treatment is introduced in patients infected with HCV receiving direct-acting antiviral therapy |
| **Hepatitis B virus infection** | |
| 104       | HBV infection: do not suspend long-term antiviral therapy  
Do not suspend long-term antiviral therapy with nucleosidic analogues in patients who are infected with HBV without an evaluation by a specialist |
| **Prevention/prophylaxis** | |
| 105       | Prophylaxis for *Pneumocystis jiroveci* pneumonia and bone marrow transplant  
Prescribe or continue prophylactic treatment against *Pneumocystis* pneumonia in patients having received a bone marrow transplant |
| 106       | Prophylaxis for *P jiroveci* pneumonia and solid organ transplant  
Prescribe or continue prophylactic treatment against *Pneumocystis* pneumonia in patients having received a solid organ transplant and receiving immunosuppressants |
| 107       | Prophylaxis for *P jiroveci* pneumonia and HIV infection  
Prescribe or continue prophylactic treatment against *Pneumocystis* pneumonia in patients who are HIV-infected with a CD4 count of<200 cells/mm3 |
| 108       | Prophylaxis for *P jiroveci* pneumonia and highly immunosuppressive drugs  
Consider prophylactic treatment against *Pneumocystis* pneumonia in patients receiving highly immunosuppressive treatments* |
| 109       | Isoniazid and the prevention of peripheral neuropathy: start vitamin B6  
Prescribe a vitamin B6 supplement in patients who are treated with isoniazid and with a risk of deficiency* or showing signs of peripheral neuropathy |
| **Proper use of antibiotics** | |
| 110       | Re-evaluate empiric antibiotic treatment within 24–72 hours  
Re-evaluate empiric antibiotic treatment within 24–72 hours after it is started and adapt it based on the patient’s clinical condition and the results of bacteriological samples |
| 111       | Antibiotics through parenteral route: re-evaluate the route of administration  
Favour the OR* as soon as the patient’s clinical condition allows it, considering the bacteriological documentation and choosing an antibiotic with good oral bioavailability* |
| 112       | Proper use of antibiotics: re-evaluate the duration of therapy  
Re-evaluate the continuation of effective antibiotic treatment after 5–7 days. Continuation of the treatment past 10 days should be reserved for certain serious infections or situations* |
| 113       | Aminoglycoside and vancomycin: therapeutic drug monitoring  
Monitor plasma concentrations for antibiotics with a dose-dependent toxicity* in the case of suspicion of toxicity or risk situation for toxicity** and/or in the case of risk of underdosing**. Then, adjust the dosing regimens |
| 114       | Macrolides and long QT syndrome or drugs that prolong the QT interval  
Exercise caution when using macrolides, in particular azithromycin, in patients with a high cardiovascular risk*, especially if combined with drugs with the potential to cause QT prolongation |
| 115       | Aminoglycosides and once-daily dosing  
Preferably use an aminoglycoside with a once-daily dosing regimen by intravenous route (30 min perfusion) combined with another antibiotic and for a duration of≤5 days (unless there is a particular situation*) |
| **ENDOCRINOLOGY** | |
| **Diabetes mellitus** | |
| 116       | DM: adjust therapy according to HbA1c targets  
Adjust the antidiabetic treatment in a customised manner, optionally combining several molecules, to obtain a HBA1c target that is adapted to the patient* |
| 117       | DM: avoid drugs that may alter the blood glucose level*  
Exercise caution in using drugs that may alter the blood glucose level** in patients with diabetes and perform a close monitoring of blood glucose* in case of use |
| 118       | DM: CS and blood glucose monitoring  
Monitor blood glucose closely if CS are introduced to patients with diabetes or patients with glucose intolerance, and optionally adjust the antidiabetic treatment |

---

*Desnoyer A, et al. BMJ Open 2017;7:e016070. doi:10.1136/bmjopen-2017-016070*
### Table 3  Continued

**PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine**

| 119 | Other | DM or microalbuminuria*/proteinuria and HTN: start ACEI or ARB (nephroprotective effects)  
Favour an ACEI or ARB combined or not with another first-line antihypertensive drug to treat HTN in patients with diabetes or patients with microalbuminuria*/proteinuria |
| 120 | UP    | DM: start statins in patients with a high or very high cardiovascular risk  
Prescribe or continue statins in patients with diabetes with a high or very high cardiovascular risk* |
| 121 | UP    | DM: start low-dose aspirin in patients with a high cardiovascular risk or as secondary prevention  
Consider a low-dose aspirin treatment* in patients with diabetes with a high cardiovascular risk**. Prescribe it as secondary prevention of cardiovascular events |
| 122 | UP    | T2DM: start metformin as a first-line treatment  
Prescribe metformin as a first-line treatment for pharmacological treatment for T2DM |
| 123 | OP    | T2DM and metformin: withhold metformin in unstable conditions  
If necessary, withhold metformin in hospitalised patients with diabetes in unstable conditions, in case of surgery or in case of the injection of an iodine contrast product, particularly with polymorbidity or renal failure |
| 124 | Other | DM or microalbuminuria*/proteinuria and HTN: start ACEI or ARB (nephroprotective effects)  
Favour an ACEI or ARB combined or not with another first-line antihypertensive drug to treat HTN in patients with diabetes or patients with microalbuminuria*/proteinuria |
| 125 | Other | DM and renal failure: adjust the doses of antidiabetics  
Monitor blood glucose and adjust the doses of antidiabetics* in the case of impaired renal function |

#### Thyroid disorders

| 126 | Other | Hypothyroidism: measure the serum TSH 6 weeks after changing the levothyroxine dose  
Measure the serum TSH 6 weeks after changing the levothyroxine dose or after any change in a levothyroxine-based agent and assess whether a new titration of the dose is necessary |
| 127 | Other | Hypothyroidism: levothyroxine and usual mode of administration  
Continue treatment with levothyroxine under the usual mode of administration  
In the case of initiation, favour the administration on an empty stomach in the morning* in the absence of substances that may decrease its absorption** |
| 128 | OP    | Hypothyroidism: levothyroxine and OR unavailable  
It is not necessary to administer levothyroxine parenterally to dysthyroidal patients with stable euthyroidism who are unable to receive oral treatment for an anticipated duration of \(<7 days |
| 129 | OP    | Thyroid disorders: be careful with drugs that may induce hypothyroidism or hyperthyroidism*  
Monitor the TSH before and 6 weeks after the introduction of a treatment that may induce thyroid disorders* |
| 130 | UP    | Hyperthyroidism: start a beta-blocker  
Consider prescribing a beta-blocker in patients with hyperthyroidism, particularly at the beginning of pharmacological management |

#### Contraception

| 131 | DDI  | Contraception and DDIs  
Verify contraceptive use in all hospitalised women of childbearing age, and if necessary monitor the lack of DDI with the treatments* that are received or started during hospitalisation |

#### OPHTHALMOLOGY

**Glaucoma**

| 132 | UP    | Glaucoma and medication history at admission: continue ophthalmic drop treatment  
Verify ophthalmic drop intake during drug medication history at admission and continue glaucoma treatment in patients who are treated for that indication |
| 133 | OP    | Acute angle-closure glaucoma: drugs that may exacerbate acute glaucoma  
Avoid the use of drugs that may induce acute closed-angle glaucoma* in at-risk individuals who have not had an iridotomy |

#### DEPENDENCIES

**Addictions and hospitalisation**

| 134 | Other | Addiction: rapid interview and brief intervention  
Perform a rapid interview to detect addiction if an addiction problem is suspected, and if needed, perform a brief intervention to address the addiction problem |

Continued
**Table 3** Continued

PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine

| Alcohol dependence | 135 | Alcohol dependence: rapid identification test for alcohol dependence and brief intervention |
|--------------------|-----|--------------------------------------------------------------------------------------------|
| Other              |     | In case of suspicion, perform a rapid identification test for alcohol dependence in hospitalised patients |
| 136                | UP  | Alcohol withdrawal: start close monitoring and optional prophylaxis with a BZD* |
|                    |     | Provide close monitoring using a predictive evolution scale and optionally prescribe an appropriate oral BZD* in hospitalised patients with a risk of alcohol withdrawal. If close monitoring is not feasible, prescribe an appropriate oral BZD* |
| 137                | UP  | Alcohol dependence: start vitamin B1 and multivitamins |
|                    |     | Prescribe treatment with vitamin B1 in alcohol-dependent patients and multivitamins in case of malnutrition |

| Tobacco use and tobacco withdrawal | 138 | Tobacco dependence: start nicotine replacement therapy if needed |
|-----------------------------------|-----|----------------------------------------------------------------|
|                                   |     | If needed, prescribe treatment with a nicotine replacement therapy for hospitalised smokers |
|                                   | 139 | Tobacco dependence and chronic ischaemic heart disease/respiratory diseases: start smoking cessation intervention |
|                                   |     | Offer assistance for tobacco cessation to any patient suffering from ischaemic heart disease or chronic respiratory disease |

| Benzodiazepine dependence | 140 | BZD dependence: continue BZD treatment at the usual dose during the acute phase of hospitalisation |
|--------------------------|-----|--------------------------------------------------------------------------------------------------|
|                         |     | Continue BZD treatment at the usual dose for hospitalised patients with BZD dependency. Suggest a progressive tapering out of the acute phase of hospitalisation |

| Opioid dependence | 141 | Opioid dependence: continue maintenance opioid substitution |
|-------------------|-----|-----------------------------------------------------------|
|                   |     | Continue opioid substitution treatment at the usual doses or an equivalent treatment, while respecting the rules of dose equivalence, in hospitalised patients with an opioid dependency and receiving a substitution treatment |
|                   | 142 | Opioid dependence and buprenorphine: be careful when prescribing opioid analgesics |
|                   |     | Avoid or be careful when prescribing methadone or a step 2 or 3 opioid analgesic in patients receiving buprenorphine substitution |

**OBESITY**

Proper use of drugs in the case of obesity

| Obese patients: increase doses of injectable antithrombotic agents (LMWH/heparin/fondaparinux) | 143 | Obese patients: increase doses of injectable antithrombotic agents (LMWH/heparin/fondaparinux) |
|-----------------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------|
| Increase the doses of heparin or fondaparinux in obese patients requiring antithrombotic treatment |     |                                                                                            |
| Obese patients: prefer oral and intravenous routes | 144 | Obese patients: prefer oral and intravenous routes |
| Favour the oral and intravenous routes in obese patients when they are appropriate for the patient and the drug |     |                                                                                            |
| Obese patients: Adjust initial doses of aminoglycosides according to the adjusted body weight* | 145 | Obese patients: Adjust initial doses of aminoglycosides according to the adjusted body weight* |
| Adjust the initial dose of aminoglycosides in obese patients according to the adjusted body weight* and then re-evaluate the dose based on the plasma concentrations |     |                                                                                            |
| Obese patients: Adjust the initial doses of vancomycin according to the total body weight | 146 | Obese patients: Adjust the initial doses of vancomycin according to the total body weight |
| Adjust the initial dose of vancomycin in obese patients according to the total body weight and then re-evaluate the dose based on the plasma concentrations |     |                                                                                            |

**PHARMACOLOGY and TOXICOLOGY**

Clinical pharmacology

| Allergies and new medication: rule out allergies | 147 | Allergies and new medication: rule out allergies |
|-------------------------------------------------|-----|-------------------------------------------------|
| Verify the absence of allergies when a new medication is introduced in patients |     |                                                |
| QT prolongation: drugs that prolong the QT interval | 148 | QT prolongation: drugs that prolong the QT interval |
| Avoid the use of drugs* that may prolong the QT interval in patients suffering from congenital long QT syndrome or at risk of torsade de pointes** |     | Avoid the use of drugs* that may prolong the QT interval in patients suffering from congenital long QT syndrome or at risk of torsade de pointes** |
| Serotonin syndrome: drugs that are associated with serotonin syndrome | 149 | Serotonin syndrome: drugs that are associated with serotonin syndrome |
| Avoid prescribing two drugs that may induce serotonin syndrome* when an alternative is available or monitor patients closely |     | Avoid prescribing two drugs that may induce serotonin syndrome* when an alternative is available or monitor patients closely |
| Drug-induced Parkinsonism: drugs that may induce extrapyramidal symptoms | 150 | Drug-induced Parkinsonism: drugs that may induce extrapyramidal symptoms |
| Avoid prescribing drugs that may induce extrapyramidal symptoms in patients with that syndrome |     | Avoid prescribing drugs that may induce extrapyramidal symptoms in patients with that syndrome |
36 (23%) to overprescription, 16 (10%) to interactions and 34 (21%) to other PIM (eg, insufficient drug monitoring, incorrect dose adjustment, wrong choice of medication). The rationales for the statements are presented in online supplementary table 2, along with 233 references, 116 recommendations (eg, dose adjustment, alternatives and monitoring), 93 remarks (eg, definitions, reminders and useful lists of drugs) and 24 useful web links.

**Fourth step: Forward/back-translation**

Among the 160 statements that were forward/back-translated, 16 were identified as having inadequate expression and were then corrected. The tool is available, both in French and in English (http://app.pimcheck.org/#/accueil/en).

**Fifth step: electronic tool development**

One hundred and ninety-three synonyms of the 52 subdomains included in the tool and 1635 medications were identified. To create the ‘Screening’ function, each statement was associated with corresponding subdomains and medications and an algorithm of approximately 31 000 lines was developed. This algorithm allows to ‘switch on’, or ‘switch off’, statements, depending on comorbidities and medications selected by the user. The ‘Favourites’ function created gives quick access to statements identified as

---

**Table 3 Continued**

| PIM-Check: Potentially Inappropriate Medication checklist for Patients in Internal Medicine |
|---------------------------------|---------------------------------|
| **151 OP** | G6PD deficiency: drugs that may cause haemolytic anaemia* Avoid or use with caution drugs that may cause haemolytic anaemia* in patients with G6PD deficiency |
| **152 UP** | Antifolates* and haematotoxicity: prescribe folinic acid to patients with haematotoxicity related to taking antifolates* |

**Drug–drug interactions**

| **153 DDI** | DDI: strong enzyme inducers and inhibitors* Adapt the doses of substrate drugs as needed if a strong enzyme inducer or inhibitor* is introduced, and monitor the clinical response |
| **154 DDI** | DDI: re-evaluate drug doses within 15 days following the discontinuation of a strong enzyme inducer Re-evaluate doses of substrate drugs within 15 days following the cessation of a strong enzyme inducer |

**TRANSPLANTS**

| **155 UP** | Immunosuppressive drugs*: therapeutic drug monitoring Continue immunosuppressive treatment* in transplanted patients; do not modify that treatment without consulting the referring physician but monitor the plasma or blood concentrations** in case of altered renal function or in the presence of a health condition that may influence the plasma or blood concentrations |

| **156 DDI** | Immunosuppressive drugs and DDIs Evaluate the risk of DDIs, and optionally monitor plasma or blood concentrations* if a new treatment is introduced or if a drug is removed from a transplanted patient receiving immunosuppressants (in particular with CYP and/or Pgp inducers/inhibitors**) |

**VACCINATIONS**

| **157 UP** | Annual influenza vaccination Offer an annual influenza vaccination to patients with a high risk of complications* |
| **158 UP** | Pneumococcal vaccination: high-risk patients* Offer pneumococcal vaccination to patients at high risk of invasive pneumococcal infection* |
| **159 OP** | Vaccination and immunocompromised patients*: avoid live attenuated vaccines Avoid the use of live attenuated vaccines in immunocompromised patients* |
| **160 UP** | Vaccines: check vaccination status Verify the vaccination status of hospitalised patients, and suggest catch-up for mandatory and recommended vaccines, if necessary* |

Colour code of PIM: green stands for UPs, red for OPs, amber for DDIs and grey for other kind of PIM.

* , ** Stars refers to information that is available in online supplementary table 2.

ACEI, angiotensin conversion enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin II receptor antagonists; BP, blood pressure; BPH, benign prostatic hyperplasia; BZD, benzodiazepine; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disorder; CrCI, creatinine clearance; CS, corticosteroids; CYP, cytochrome P450; DDI, drug–drug interaction; DOAC, direct-acting oral anticoagulant; DM, diabetes mellitus; DVT, deep vein thrombosis; ESA, erythropoiesis-stimulating agent; G6PD: glucose-6-phosphate dehydrogenase; GDU, gastroduodenal ulcer; HAART, highly active antiretroviral therapy; HB, haemoglobin; HBA1c, glycated haemoglobin; HBV, hepatitis B virus; HCV: hepatitis C virus; HF, heart failure; HTN, hypertension; ICS, inhaled corticosteroids; INR:, international normalised ratio; LVEF, left ventricular ejection fraction; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drug; OP, overprescription; OR, oral route; PE, pulmonary embolism; Pgp, P-glycoprotein, PPIs, proton pump inhibitors; RA, rheumatoid arthritis; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack; TSH, thyroid-stimulating hormone; T2DM, type 2 diabetes mellitus; UP, underprescription; VAS, visual analogue scale; Vitamin B1, thiamine; Vitamin B6, pyridoxine; Vitamin K antagonist; VTE, venous thromboembolism.
favourite, and the ‘Learning’ function gives access to the list of all statements included in PIM-Check, those unread and those already read. Details regarding the conception of the tool, direct access to the references (n=333) and useful links (n=29) (through URL links), publications related to the tool and a contact section, are also available (http://www.pimcheck.org/en/).

Interpretation

PIM-Check was specifically designed to assist residents and young healthcare professionals in the detection of PIM in patients typically admitted in internal medicine (excluding pregnant women, patients with low life expectancy and patients requiring palliative care). The checklist consists of 160 statements for pathologies and drugs commonly encountered in internal medicine. The checklist does not replace the judgement of physicians and pharmacists but is intended to help young healthcare professionals to improve the medication review process and to reduce the incidence of PIM. Owing to the additional data and references associated with the statements, PIM-Check should also be helpful for training students and residents in prescribing-optimisation. Because most of the statements are based on current international clinical evidence and were validated by European and North American experts, we expect that the English version of PIM-Check will be useful in many healthcare settings. Finally, the availability of an electronic version should facilitate the use of PIM-Check in daily practice.

Comparison with other studies

PIM-Check includes more medical domains (n=17) and subdomains (n=52) than do the published geriatric checklists. Some of the domains and subdomains commonly found in geriatric checklists are not included in PIM-Check (eg, falls, dementia, orthostatic hypotension and sleep apnoea). In contrast, PIM-Check includes statements related to domains, such as transplantation, dependencies, obesity, antiviral therapy and proper use of antibiotics that are not generally covered by geriatric checklists. This last domain should be useful because interventions implemented in hospitals to improve the use of antibiotics have succeeded in preventing PIM. PIM-Check also includes therapeutic classes and drugs commonly associated with preventable hospitalisation and with PIM in internal medicine (eg, non-steroidal anti-inflammatory drugs, anticoagulants, antihypertensive or antidiabetic treatments, statins, proton pump inhibitors and corticosteroids). PIM-Check is also more focused on underprescription than are geriatric checklists. Seventy-four (46%) statements in PIM-Check are related to underprescription versus 18 (37%), 34 (27%) and 71 (18%) in the Australian checklist, STOPP/START v2, and Assessing Care of Vulnerable Elders indicators v3, respectively. This can be explained by the fact that recommending preventive treatment in older populations is sometimes inappropriate. In contrast, underprescription in internal medicine patients is not rare, and occurred 1.8 times as often as overprescription;

thus, PIM-Check should be more helpful than other checklists for preventing PIM in this population.

Strengths and limitations

The Delphi method is a robust method for reaching a consensus of opinion and is commonly used for validating PIM checklists. The reliability of a Delphi survey is directly proportional to the size of the expert group. Therefore, we are confident that results from this study are robust, because the number of experts involved in our Delphi survey was high, as was the participation rate. As previously demonstrated by Chang et al, checklists with higher numbers of statements, therapeutic classes and medical domains tend to show higher rates of PIM detection, although the use of long checklists can be time-consuming. However, PIM-Check is the first checklist available as an electronic device. The ‘Screening’ function allows users to perform an analysis for a specific patient, restricting the statements displayed to those that are most relevant to that patient, depending on his/her comorbidities and prescribed medications. This function should enable users to review a prescription in less than 5 min, as can be done with STOPP/START. However, these issues need to be addressed in the future, as the ability of PIM-Check to prevent PIM.

Implications for clinicians and policymakers

In our study, experts rated the statements as being highly useful for the training of students and residents. The inclusion of additional data and references with the statements can be expected to make PIM-Check helpful for improving trainee awareness of good prescription practices. Moreover, as previously demonstrated, interactive techniques in medication education and training in the use of systematic tool to reduce PIM are effective in improving prescribing-skill and patient care. The progressive learning function included in the electronic version of PIM-Check may constitute an effective intervention to improve prescribing performance. Finally, PIM-Check could be helpful for researchers and policymakers because it could be used to estimate the incidence of PIM in various settings, to evaluate prescription quality and safety and to evaluate factors and costs associated with PIM, as it has been proposed for STOPP/START and the Beers Criteria.

Unanswered questions and future research

The next step will be to evaluate the incidence of PIM detected and prevented using PIM-Check in various healthcare settings. It will also be of interest to determine whether the use of PIM-Check, like the use of STOPP/START, is significantly associated with reductions in adverse drug events and improvement in young healthcare professionals prescribing training. We will test the English version of PIM-Check in non-French-speaking countries. Another project might be to integrate PIM-Check as a clinical decision support system in electronic health records, to assist physicians and pharmacists in their clinical practice. Finally, like geriatric checklists, PIM-Check will need to be updated in a
few years as new research is published and new drugs are licensed.

CONCLUSION
In conclusion, this study offers an electronic prescription-screening checklist, including 160 statements. The application of this checklist combined with clinical judgement should contribute to help young physicians and pharmacists in their training and clinical practice, to detect and reduce PIM. In the context of expansion and pharmacists in their training and clinical practice, judgement should contribute to help young physicians.

Author affiliations
1Department of Pharmacy, Hôpitaux Universitaires de Genève, Geneva, Switzerland
2Department of Pharmacy, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
3Department of Pharmacy, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
4Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
5UMR996—Inflammation, Chemokines and Immunopathology, Inserm, Clamart, France
6Department of Clinical Pharmacology and Toxicology, Hôpitaux Universitaires de Genève, Geneva, Switzerland
7Section of Pharmaceutical Sciences, Université de Genève, Université de Lausanne, Geneva, Switzerland
8Department of General Internal Medicine, Hôpitaux Universitaires de Genève, Geneva, Switzerland

Acknowledgements
The following people constituted the research group in charge of the study design: AD, BG, ALB, VP, MB, CFC, JD, AP, CS, and PB. AD, ALB, VP, MB, CFC, BG, and PB were responsible for the selection of the medical domains and subdomains to be addressed in PIM-Check. We are grateful to the following medical specialists from the Hôpitaux Universitaires de Genève for their individual contributions to the semi-structured interviews: Victor Bancila (psychiatry), Philippe Bichard (gastroenterology), François-Boehlen (haematology and haemostasis), Sandra Boechnec (endocrinology), Yassine Bouatou (nephrology), JD (clinical pharmacology and pain clinic), Georg Ehret (cardiology), Stefan Harbarth (infectious diseases), Jean-Paul Janssens (pneumology), Loïc Locatelli (psychiatry and addiction), Philippe Meyer (cardiology and hypertension), Michael Nissen (rheumatology), Zoltan Pataky (obesity), CS (clinical pharmacology), Tarek Shaarawy (ophthalmology), Catherine Storemann (nephrology), and Serge Vulliémoz (neurology). ALB, VP, MB, Olivier Grosquin (HUG, Geneva, Switzerland) and Christophe Marti (HUG, Geneva, Switzerland) were involved in the selection of statements before the first round of the Delphi survey. Wethank the Delphi panel of experts: Annie Athouel (pharmacy, Le Mans, France), Aurélie Barral-Tran (pharmacy, K. Bicêtre, France), Olivier Bercelay (internal medicine, Valais romand, Switzerland), Guy Beuken (general internal medicine, Louvain, Belgium), Dorine Castillo (pharmacy, A. Vésale, Belgium), Remy Charette (pharmacy, McGill, Canada), Delphine Chenevix (pharmacy, Cognac, France), Emmanuelle Demessin (general internal medicine, Le Mans, France), Maxime Dore (pharmacy, Sacré-Cœur, Canada), Guillaume Faubert (pharmacy, Maisonneuve-Rosemont, Canada), Séverine Foucher (pharmacy, A. Béclère, France), Antoine Garnier (internal medicine, CHUV, Switzerland), Nathalie Giliard (pharmacy, Saint-Kuc, Belgium), BG, Pascal Guillemi (internal medicine, Macon, France), Bernard Hanson (internal medicine, IRS Sud, Belgium), Ly Khuhl (internal medicine, McGill, Canada), Pierre-Oliver Lang (internal medicine, Genolier, Switzerland), Anne-Marie Mansour (internal medicine, Sacré-Cœur, Canada), Ariane Mouzon (pharmacy, Mont-Godinne, Belgium), Carole Nachar (pharmacy, CHUV, Switzerland), Jean-Baptiste Nicolas (internal medicine, Mont-Godinne, Belgium), Nicolas Noel (internal medicine, K. Bicêtre, France), Pauline Papin (pharmacy, Saint Jean, Belgium), Marc Parent (pharmacy, Québec, Canada), Julie Peeterbroeck (pharmacy, A. Vésale, Belgium), Rachel Pham (pharmacy, IRS Sud, Belgium), For Renato (internal medicine, A. Béclère, France), Thibault Richard (internal medicine, A. Vésale, Belgium), Thierry Romanet (pharmacy, Grenoble, France), Nicolas Schaad (pharmacy, Morges, Switzerland), Mathieu Sergerie (internal medicine, Maisonneuve-Rosemont, Canada), Iletona Stifti (internal medicine, Le Cognac, France), Jérôme Stémenmann (internal medicine, HUG, Switzerland), Pierre-Alain Triverio (internal medicine, Jura bernois, Switzerland), Vera Vorstenbosch (pharmacy, Valais romand, Switzerland), Joël Wermelie (pharmacy, Jura bernois, Switzerland), Claire Wintenberger (internal medicine, Grenoble, France), Philippe Zouai (general internal medicine, Grenoble, France). ALB, VP and MB made up the investigator triangulation group. We thank Elsevier Translation Service for the forward translation of PIM-Check. CS, AD, BG, and ALB participated in the back translation. Wethank Rolf Haurn (Geneva School of Business Administration (HEG)) and Alain Lorentz (for the web development and the web design of PIM-Check website and web/mobile application and Carlotta Sheaaron (Shearson Editorial Services) for editing the manuscript.

Contributors
All authors constituted the research group in charge of the design of the study and contributed to the conception of the work. AD, ALB, VP, MB, CFC, BG and PB were responsible for the selection of the medical domains and subdomains to be addressed in PIM-Check. ALB, VP and MB made up the investigator triangulation group. CS, AD, BG and ALB participated in the back translation of the tool. AD, PB and BG were responsible for the acquisition, analysis and interpretation of data for the work. AD, ALB, PB and BG drafted the work. VP, MB, CFC, JD, AP and CS revised it critically for important intellectual content. All authors approved the final version of the paper to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests
None declared.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
Full dataset are available with open access at www.pimcheck.org/en/ or from the corresponding author at audedesnoyer@gmail.com.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. IMS Institute for Healthcare Informatics. Advancing the responsible use of medicines - Applying levers for change. 2012. http://www.imshealth.com/en/thought-leadership/ims-institute/reports/responsible-use-of-medicines-report (accessed 17 Jan 2017).
2. International Pharmaceutical Federation. FIP Statement of professional standards medication errors associated with prescribed medication, available. 1999. http://www.fip.org/www/uploads/database_file.php?id=229&table_id= (accessed 17 Jan 2017).
3. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533–43.
4. Blis HS, Viktt KK, Reikvam A, et al. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol 2004;60:651–8.
5. Blis HS, Viktt KK, Moger TA, et al. Characteristics of drug-related problems discussed by hospital pharmacists in multidisciplinary teams. Pharm World Sci 2006;28:152–8.
6. Bondesson A, Eriksson T, Kragh A, et al. In-hospital medication reviews reduce unidentified drug-related problems. Eur J Clin Pharmacol 2013;69:647–55.
7. Guignard B, Bonnabry P, Perrier A, et al. Drug-related problems identification in general internal medicine: the impact and role of the clinical pharmacologist and pharmacist. Eur J Intern Med 2015;26:399–406.
8. Spinevina A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173–84.
9. Hill-Taylor B, Sketris I, Hayden J, et al. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanitarian and economic impact. J Clin Pharm Ther 2013;38:360–72.
10. Beers MH, Ouslander JG, Rillinger I, et al. Explicit criteria for determining inappropriate medication use in nursing home
residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991;151:1825–32.
11. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. an update. Arch Intern Med 1997;157:1531–6.
12. Fick DM, Cooper JW, Wadke WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716–24.
13. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616–31.
14. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in Older adults. J Am Geriatr Soc 2015;63:2227–46.
15. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: acove project overview. Ann Intern Med 2001;135:642–6.
16. Wenger NS, Roth CP, Shekelle P, et al. Introduction to the assessing care of vulnerable elders-3 quality Indicator measurement set. J Am Geriatr Soc 2007;55(Suppl 2):S247–S252.
17. Basger BJ, Chen TF, Moles RJ. Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method. BMJ Open 2012;2:e001431.
18. Gallagher P, Ryan CD, Byrne S, et al. STOPP (Screening Tool of Older person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment), Consensus validation. Int J Clin Pharmacol Ther 2008;46:72–83.
19. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44:213–8.
20. Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging 2010;27:947–57.
21. Chang CB, Chen JH, Wen CJ, et al. Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit criteria. Br J Clin Pharmacol 2011;72:482–9.
22. Desnoyer A, Guignard B, Lang PO, et al. [Potentially inappropriate medications in geriatrics: Which tools to detect them?]. Presse Med 2016;45:957–70.
23. Lavan AH, Gallagher PF, O’Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging 2016;11:857–66.
24. Viktis JK, Blix HS, Moger TA, et al. Polypharmacy as commonly defined is an Indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007;63:187–95.
25. Longo D, Fauci A, Kasper D, et al. Harrison’s principles of internal medicine. 18th ed, 2012.
26. Institute for Safe Medication Practices – ISMP List of High-Alert Medications in Acute Care Settings. 2014. http://www.ismp.org/tools/highalertmedications.pdf (accessed 17 Jan 2017).
27. Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755–65.
28. Boulkeddri R, Abdoul H, Loustau M, et al. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 2011;6:e20476.
29. Prot-Labarthe S, Weil T, Angoulvant F, et al. POPI (Pediatrics: omission of prescriptions and inappropriate prescriptions): development of a tool to identify inappropriate prescribing. PLoS One 2014;9:e101171.
30. Patton MQ. Enhancing the quality and credibility of qualitative analysis. Health Serv Res 1999;34:1189–208.
31. World Health Organization. Process of translation and adaptation of instruments. Available from: http://www.who.int/substance_abuse/research_tools/translation/en/ (accessed 17 Jan 2017).
32. Centre Belge d’Information Pharmacothérapeutique. Base De données DME. 2015. http://www.cbib.be/fr/download (assessed 17 Jan 2017).
33. Sécurité sociale, assurance maladie. La base des médicaments et Informations Tarifaires, 2015. http://www.cagole.ext.cnamts.fr/codict/bdm_it/index presentation.php?site=AMELI (accessed 17 Jan 2017).
34. Health Canada. Drug Product Database. 2015. http://www.hc-sc.gc. ca/dhp-mps/prodpharma/databas dopd_bdpp_data_extract-eng. php (accessed 17 Jan 2017).
35. Confédération suisse Liste Des spécialités. http://www. listedesspecialites.ch/Default.aspx (assessed 17 Jan 2017).
36. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:CD003543.
37. O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing 2008;37:138–41.
38. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63:1025–9.
39. Dalkey NC. The Delphi Method: an experimental study of Group Opinion. Santa Monica, CA: RAND Corporation, 1969. http://www.rand. org/pubs/research_memoranda/RM5888 (assessed 17 Jan 2017).
40. Gallagher PF, O’Connor NN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther 2011;89:845–54.
41. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care 2005;21:380–5.
42. Keijser C, van Doorn AB, van Kalles A, et al. Structured pharmaceutical analysis of the systematic Tool to reduce Inappropriate Prescribing is an effective method for final-year medical students to improve polypharmacy skills: a randomized controlled trial. J Am Geriatr Soc 2014;62:1353–9.
43. van der Hooft CS, Jong GW, Dieleman JP, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria--a population-based cohort study. Br J Clin Pharmacol 2005;60:137–44.
44. Stevens MB, Hastings SN, Powers J, et al. Enhancing the Quality of Prescribing Practices for older veterans discharged from the Emergency Department (EQUIPPED): Preliminary results from enhancing Quality of Prescribing Practices for older veterans discharged from the Emergency Department, a novel multicomponent Interdisciplinary Quality Improvement Initiative. J Am Geriatr Soc 2015;63:1025–9.
45. Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the northern Ireland enhanced Prescribing Database. Eur J Clin Pharmacol 2012;68:1425–33.
46. Bongue B, Laroche ML, Gutton S, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. Eur J Clin Pharmacol 2011;67:1291–9.
47. Agency for Healthcare Research and Quality (AHRQ) - National Healthcare Quality Report, 2012. Available at: archive.ahrq.gov/ research/findings/nhqdr/nhqdr12/2012nhqr.pdf
48. National Committee for Quality Assurance. Proposed changestoxisting measurefor HEDIS®1 2016: Medication Reconciliation Post-Discharge (MRP). 2015. http://www.ncqa.org/Portals/O/PublicComment/HEDIS2016/10.Medication Reconciliation Post-Discharge.pdf (accessed 17 Jan 2017).
49. Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011;171:1013–9.
50. Erkut S. Developing multiple language versions of Instruments for Intercultural Research. Child Dev Perspect 2010;4:19–24.
51. Shekelle PG, MacLean CH, Morton SC, et al. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001;135:847–52.